- Home
- CRIS vs CMMB Comparison
CRIS vs CMMB Comparison
Compare CRIS & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRIS | CMMB |
|---|---|---|
| Founded | 2000 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.0M | 11.2M |
| IPO Year | 2000 | 2023 |
Fundamental Metrics
Financial Performance| Metric | CRIS | CMMB |
|---|---|---|
| Price | $0.69 | $1.67 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | $17.00 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 496.7K | 40.2K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 91.57 | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | ★ $9,898,000.00 | N/A |
| Revenue This Year | $27.10 | N/A |
| Revenue Next Year | $67.74 | N/A |
| P/E Ratio | ★ N/A | $42.25 |
| Revenue Growth | ★ 31.50 | N/A |
| 52 Week Low | $0.49 | $0.87 |
| 52 Week High | $3.13 | $3.86 |
Technical Indicators
Market Signals| Indicator | CRIS | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 48.95 | 49.25 |
| Support Level | N/A | $1.44 |
| Resistance Level | $1.04 | $1.86 |
| Average True Range (ATR) | 0.08 | 0.13 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 64.94 | 54.76 |
Price Performance
Historical ComparisonAbout CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.